Final answer:
The second drug of choice for treating MI typically consists of antiplatelet therapy, such as clopidogrel plus aspirin, or β-blockers like metoprolol and propranolol, which help to reduce cardiovascular events post-MI by blocking β-receptors.
Step-by-step explanation:
The second drug of choice for treatment in patients with myocardial infarction (MI) often includes antiplatelet therapy or β-blockers. Antiplatelet drugs such as clopidogrel combined with aspirin are commonly used in dual antiplatelet therapy (DAPT), especially when stents are placed or in cases of ST-elevation myocardial infarction (STEMI) to reduce cardiovascular events. β-blockers, such as metoprolol and propranolol, are sympatholytic drugs that block β-receptors, leading to vasodilation and reduced heart rate, improving cardiac function post-MI. Other options may include calcium channel blockers and angiotensin receptor blockers (ARBs) like valsartan or losartan, depending on the specific circumstances and contraindications of the patient.